Meeting
2014 ASCO Annual Meeting
A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.
Authors
Florian Heidel
Otto von Guericke University of Magdeburg, Magdeburg, Germany
Florian Heidel , Vincent Ribrag , Alessandro M. Vannucchi , Jean-Jacques Kiladjian , Francesco Passamonti , Amjad Hayat , Eibhlin Conneally , Thomas Kindler , Bruno Martino , Daniel B Lipka , Suddhasatta Acharyya , Florence Binlich , Tracy Liu , Song Mu , Claire N. Harrison
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders
Clinical Trial Registration Number
NCT01433445
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 7022^)
DOI
10.1200/jco.2014.32.15_suppl.7022
Abstract #
7022^
Poster Bd #
14
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.
First Author: Vikas Gupta
Poster
2024 ASCO Annual Meeting
A phase Ib, open-label study of add-on therapy with CK0804 in participants with myelofibrosis and suboptimal response to ruxolitinib.
First Author: Lucia Masarova
Poster
2024 ASCO Annual Meeting
H3B-6545 + palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).
First Author: Stephen R. D. Johnston
Poster
2024 ASCO Annual Meeting
A phase 1/2 dose escalation and expansion study of sonodynamic therapy with SONALA-001 in combination with Exablate 4000 Type 2.0 MR-guided focused ultrasound in patients with progressive or recurrent glioblastoma (rGBM).
First Author: Dimitris Placantonakis